We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study.
- Authors
Gong, Zimu; Umoru, Godsfavour; Monge, Jorge; Shah, Nishi; Mohyuddin, Ghulam Rehman; Radhakrishnan, Sabarinath Venniyil; Chakraborty, Rajshekhar; Rasche, Leo; Schinke, Carolina; D'Souza, Anita; Mohan, Meera
- Abstract
This letter published in the Blood Cancer Journal examines the adverse effects and non-relapse mortality of BCMA-directed T cell therapies in multiple myeloma. The authors analyzed the FDA Adverse Event Reporting System database to identify reports of adverse effects associated with these therapies. They found that while these therapies have been effective in treating multiple myeloma, they also have distinct toxicity profiles, including cytokine release syndrome, neurotoxicity, and the risk of infections. The study provides data on the most reported adverse events and mortality rates associated with three different therapies: cilta-cel, ide-cel, and teclistamab. The authors suggest that clinicians should consider these toxicity profiles when choosing treatments, but acknowledge the limitations of the study.
- Subjects
MULTIPLE myeloma; DATABASES; T cells; CELLULAR therapy; MEDICAL personnel; MOVEMENT disorders
- Publication
Blood Cancer Journal, 2024, Vol 14, Issue 1, p1
- ISSN
2044-5385
- Publication type
Article
- DOI
10.1038/s41408-024-01023-9